Evidence map›Paper›PMID 40038143›Full record

ReviewAAPS PharmSciTech2025

Delving Into Nanoparticle Systems for Enhanced Drug Delivery Technologies.

Nimra Abaidullah, Khalid Muhammad, Yasir Waheed

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nimra AbaidullahDepartment of Industrial Biotechnology, Atta-Ur-Rehman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, 4400, Pakistan.
Khalid MuhammadDepartment of Biology, College of Science, UAE University, 15551, Al Ain, UAE.
Yasir WaheedNUST School of Health Sciences, National University of Sciences and Technology (NUST), H-12 Sector, Islamabad, 44000, Pakistan. yasir_waheed_199@hotmail.com.ORCID http://orcid.org/0000-0002-5789-4215

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology, based on the utilization of nanoparticles, has revolutionized drug delivery techniques, offering groundbreaking methods for managing and diagnosing intricate ailments over the past four decades. This article aims to underscore how the use of these particles has been used to treat previously incurable diseases such as cancer, Alzheimer's, and Parkinson's disease. Recently, the integration of diagnostic imaging and targeted therapy using theranostic nanoparticles has improved cancer treatment precision. Moreover, exosome-based drug delivery has demonstrated high in vivo biocompatibility and antigen-carrying ability during vaccine development. The unique properties of these tiny particles enable their transport to specific locations inaccessible to large drug molecules. The development of these nanodrugs by either encapsulation or adsorption of drugs on particles has allowed the loading of both hydrophilic and hydrophobic drugs. Innovative engineering approaches have enabled the engineering of shear-sensitive nanoparticles for site-targeted drug release, which eliminates the requirement for frequent doses, which is common in conventional drug delivery. Factors such as size, shape as well as surface modification are considered during the top-down and bottom-up approaches for engineering nanoparticle-based systems. However, issues related to scaling up manufacturing, long-term safety, and regulatory approval for these techniques must be resolved. The use of these drug delivery systems offers many therapeutic advantages. This article examines the application of these systems across various medical domains including cancer treatment, infectious diseases, cardiovascular disorders, central nervous system ailments, and ophthalmic conditions. This fusion of nanotechnology with drug delivery has the potential to elevate healthcare standards in the future by introducing innovative frameworks for revolutionizing therapeutic practices.

Indexed as

Drug Delivery SystemsNanoparticle Drug Delivery SystemNanoparticlesAnimalsDrug CarriersDrug LiberationHumansNanotechnologyNeoplasmsDrug CarriersNanoparticle Drug Delivery Systemcontrolled drug releasedrug carriersnanoparticlespersonalized medicinetargeted drug delivery

Identifiers

PMID40038143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.